Pathway Models Explore Our
Variability in DNA extraction from tumor biopsies and a lack of standardization are currently major sources of error in molecular laboratories. The availability of genetically defined reference standards will provide an industry standard for development and quality control of molecular assays, directly improving their accuracy.
Horizon’s suite of reference material includes standards for the increasing number of rare mutations being targeted for cancer therapeutics, which by definition are hard to find in clinical samples. Drawing upon GENESIS™ precision gene-editing technology, these reference materials reconstitute relevant cancer genes in human cell lines exactly as they occur in a patient’s tumor. This approach enables definition of virtually every characteristic of our reference standards, from the molecular constitution of the genome, to the diameter, width and DNA output associated with each product batch. We are also adapting this technology to serve immunohistochemistry (IHC) and fluorescent in-situ hybridization (FISH) based assays.
Please visit our dedicated site for Quantitative Molecular Reference Standards to gain detailed technical information, product specification and application notes.
Horizon through its diagnostics division provides renewable Genomic DNA and FFPE reference standards that contain defined allelic ratios, enabling you to: